Literature DB >> 27175240

Prognostic factors in CLL.

M Ferrarini1, G Cutrona1, A Neri2, F Morabito3.   

Abstract

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical course was somehow unexplained until studies on the CLL cell features disclosed that the CLL clones were heterogeneous and were characterized by different phenotypic and genotypic features in the different patients. On the basis of these observations, it was determined in retrospective studies that clones characterized by unmutated IGHV genes, and/or CD38 and/or ZAP-70 expression conferred a more severe prognosis to the CLL patients. Here, we present data on prospective studies carried out on Binet A-stage patients, in whom the markers were determined at diagnosis and their predictive value was assessed in comparison with chromosomal abnormalities and gene expression or micro RNA profiles. In addition, hypothesis on the potential pathogenetic role of these markers will be presented.

Entities:  

Keywords:  Binet A stage; CLL; gene expression profile; miRNA; prognostic markers; score

Year:  2012        PMID: 27175240      PMCID: PMC4851198          DOI: 10.1038/leusup.2012.17

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN: 2044-5210


  21 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

3.  Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.

Authors:  Daniela de Totero; Raffaella Meazza; Simona Zupo; Giovanna Cutrona; Serena Matis; Monica Colombo; Enrico Balleari; Ivana Pierri; Marina Fabbi; Matteo Capaia; Bruno Azzarone; Marco Gobbi; Manlio Ferrarini; Silvano Ferrini
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 4.  Chronic lymphocytic leukemia.

Authors:  Nicholas Chiorazzi; Kanti R Rai; Manlio Ferrarini
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

5.  Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival.

Authors:  Stephan Stilgenbauer; Sandrine Sander; Lars Bullinger; Axel Benner; Elke Leupolt; Dirk Winkler; Alexander Kröber; Dirk Kienle; Peter Lichter; Hartmut Döhner
Journal:  Haematologica       Date:  2007-08-01       Impact factor: 9.941

6.  Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Alison Morilla; Nnenna Osuji; Estella Matutes; Ricardo Morilla; Anna Burford; Sonia Maravelaki; Kwasi Owusu-Ankomah; John Swansbury; Roger A'Hern; Vasantha Brito-Babapulle; Daniel Catovsky
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Authors:  Adrian Wiestner; Andreas Rosenwald; Todd S Barry; George Wright; R Eric Davis; Sarah E Henrickson; Hong Zhao; Rachel E Ibbotson; Jenny A Orchard; Zadie Davis; Maryalice Stetler-Stevenson; Mark Raffeld; Diane C Arthur; Gerald E Marti; Wyndham H Wilson; Terry J Hamblin; David G Oscier; Louis M Staudt
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Authors:  J A Woyach; T S Lin; M S Lucas; N Heerema; M E Moran; C Cheney; D M Lucas; L Wei; M A Caligiuri; J C Byrd
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

View more
  2 in total

1.  Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter.

Authors:  Gregory Haskin; Mikhail Kogan
Journal:  Integr Med (Encinitas)       Date:  2018-02

2.  Diagnostic Value of Plasma miR-145 and miR-185 as Targeting of the APRIL Oncogene in the B-cell Chronic Lymphocytic Leukemia.

Authors:  Malihe Bagheri; Behzad Khansarinejad; Ghasem Mosayebi; Alireza Moradabadi; Mahdieh Mondanizadeh
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.